Certolizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 14/10/2019 |
| Rapid review completed | 14/11/2019 |
| Rapid Review outcome | A full HTA is not recommended. The NCPE recommends that certolizumab pegol not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.